Nisa Investment Advisors LLC Has $407,000 Stock Position in Shockwave Medical, Inc. (NASDAQ:SWAV)

Nisa Investment Advisors LLC lowered its position in shares of Shockwave Medical, Inc. (NASDAQ:SWAV) by 4.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,137 shares of the company’s stock after selling 98 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Shockwave Medical were worth $407,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Covestor Ltd boosted its position in Shockwave Medical by 484.9% during the 3rd quarter. Covestor Ltd now owns 427 shares of the company’s stock worth $85,000 after acquiring an additional 354 shares during the last quarter. International Assets Investment Management LLC boosted its position in Shockwave Medical by 18,122.1% during the 4th quarter. International Assets Investment Management LLC now owns 141,586 shares of the company’s stock worth $26,981,000 after acquiring an additional 140,809 shares during the last quarter. American Century Companies Inc. boosted its position in Shockwave Medical by 109.0% during the 3rd quarter. American Century Companies Inc. now owns 170,866 shares of the company’s stock worth $34,019,000 after acquiring an additional 89,094 shares during the last quarter. AMI Asset Management Corp acquired a new position in Shockwave Medical during the 4th quarter worth approximately $4,092,000. Finally, Wellington Management Group LLP raised its stake in shares of Shockwave Medical by 33.5% during the 3rd quarter. Wellington Management Group LLP now owns 1,805,771 shares of the company’s stock worth $359,529,000 after purchasing an additional 453,048 shares in the last quarter. Institutional investors and hedge funds own 95.35% of the company’s stock.

Analysts Set New Price Targets

SWAV has been the topic of a number of analyst reports. Leerink Partnrs cut Shockwave Medical from an “outperform” rating to a “market perform” rating in a research note on Friday, April 5th. SVB Leerink reiterated a “market perform” rating and set a $335.00 price objective (down previously from $361.00) on shares of Shockwave Medical in a research note on Monday, April 8th. Piper Sandler upped their price objective on Shockwave Medical from $290.00 to $360.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 2nd. Canaccord Genuity Group reiterated a “hold” rating and set a $335.00 price objective (up previously from $263.00) on shares of Shockwave Medical in a research note on Friday, April 5th. Finally, Wells Fargo & Company upped their price objective on Shockwave Medical from $200.00 to $210.00 and gave the stock an “equal weight” rating in a research note on Friday, February 16th. Ten equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Shockwave Medical presently has a consensus rating of “Hold” and a consensus target price of $309.11.

Insiders Place Their Bets

In other Shockwave Medical news, VP Trinh Phung sold 1,287 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $232.18, for a total transaction of $298,815.66. Following the transaction, the vice president now owns 32,933 shares in the company, valued at approximately $7,646,383.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Douglas Evan Godshall sold 10,000 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $231.56, for a total transaction of $2,315,600.00. Following the sale, the chief executive officer now directly owns 162,762 shares of the company’s stock, valued at approximately $37,689,168.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Trinh Phung sold 1,287 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $232.18, for a total value of $298,815.66. Following the sale, the vice president now directly owns 32,933 shares in the company, valued at $7,646,383.94. The disclosure for this sale can be found here. Insiders have sold 93,813 shares of company stock worth $23,762,679 in the last 90 days. Company insiders own 3.40% of the company’s stock.

Shockwave Medical Price Performance

SWAV opened at $327.50 on Thursday. Shockwave Medical, Inc. has a 1-year low of $157.00 and a 1-year high of $331.58. The stock’s fifty day simple moving average is $282.20 and its 200 day simple moving average is $227.08. The company has a current ratio of 11.76, a quick ratio of 10.73 and a debt-to-equity ratio of 1.09. The stock has a market cap of $12.25 billion, a PE ratio of 84.63, a price-to-earnings-growth ratio of 2.43 and a beta of 0.92.

Shockwave Medical (NASDAQ:SWAV) last posted its quarterly earnings results on Thursday, February 15th. The company reported $1.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.24. The business had revenue of $202.98 million for the quarter, compared to analysts’ expectations of $199.43 million. Shockwave Medical had a return on equity of 23.97% and a net margin of 20.17%. The firm’s revenue for the quarter was up 41.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.71 EPS. As a group, research analysts expect that Shockwave Medical, Inc. will post 4.94 earnings per share for the current year.

Shockwave Medical Company Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.